Summary
In a cooperative adjuvant chemotherapy study of osteosarcoma (COSS-80), 192 patients were registered from December 1979 to March 1982. Fortyone patients have been excluded from study because of their nonadjuvant situation, therapy-limiting clinical conditions, or inadequate diagnosis. One hundred and fifty-one patients have been randomized to receive either the drug combination bleomycin+cyclophosphamide+dactinomycin (BCD) or cisplatinum (CPL) within a course of sequential multidrug chemotherapy including adriamycin (ADR) and high dose methotrexate (HDMTX). After exclusion of 51 patients with some deviation in history and/or management 100 selected patients were randomized once more to receive in addition or not fibroblast interferon after preoperative chemotherapy and surgical removal of the primary tumor. Patients were stratified for age and sex and for site and extension of tumor as well in both randomizations. Median follow up is now 12 (1–16) months. The expected 2-year disease free survival (DFS) rate of the total doubly randomized group is 78% and of the single randomized group 76%. No difference could be discerned between recombined groups receiving BCD vs CPL or interferon vs no interferon. The effect of preoperative chemotherapy on the tumor was evaluated clinically and by histopathologic grading; 66/85 (78%) patients were judged clinically as responders with pathohistologic verification of this finding in 71% of these cases. No adverse effect arose from delaying definite surgery for preoperative chemotherapy, but initial application of chemotherapy as well as planning, preparing, and performing of the surgical procedure have been facilitated. The majority of patients received some kind of limb-salvage treatment without local recurrences so far. A statistically insignificant but intriguing tendency for a slightly higher incidence of pulmonary metastases after resection as opposed to amputation could be detected. Similar to observations in the previous study COSS-77.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cortes EP, Holland JF, Wang JJ, Sinks LF (1972) Doxorubicin in disseminated osteosarcoma. JAMA 221:1132–1138
Greenberg L, Gaynon P, Krivit W, Hammond D (1978) Use of cis-platinum diammine dichloride (CPDD) in osteogenic sarcoma in children. Proc Am Soc Clin Oncol 19:385
Ito H, Murakami K, Yanagawa T, Ban S, Sawamura H, Sakakida K, Matsuo A, Imanishi J, Kishida T (1980) Effect of human leukocyte interferon on the metastatic lung tumor of osteosarcoma. Cancer 46:1562–1565
Jaffe N (1972) Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30:1627–1631
Mosende C, Gutierrez M, Caparros B, Rosen G (1977) Combination chemotherapy with bleomycin, cyclophosphamide and dactinomycin for the treatment of osteogenic sarcoma. Cancer 40:2779–2786
Ochs JJ, Freeman AI, Douglass HO Jr, Higby DS, Mindell ER, Sinks LF (1978) cis-Dichlorodiammineplatinum(II) in advanced osteogenic sarcoma. Cancer Treat Rep 62,2:239–245
Priestman TJ (1979) Interferon: an anti-cancer agent? Cancer Treat Rep 6:223–237
Rosen G, Tan C, Sanmaneechat A, Beattie EJ Jr, Marcove R, Murphy ML (1975) The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer 35:936–945
Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC (1976) Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment osteogenic sarcoma. Cancer 37: 1–11
Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG (1979) Primary osteogenic sarcoma — The rationale for preoperative chemotherapy and delayed surgery. Cancer 43,6:2163–2177
Rosen G, Nirenberg A, Jürgens H, Tan C (1979) Phase II trial of cis-platinum in osteogenic sarcoma. Proc Am Soc Clin Oncol 20:363
Rosen G, Huvos AG, Nirenberg A, Caparros B (1981) Osteogenic sarcoma: selection of adjuvant chemotherapy based upon the response of the primary tumor to preoperative chemotherapy. Proc Am Soc Clin Oncol 22:429
Strander H, Cantell K, Ingimarsson S, Jacobsson PA, Nilsonne U, Söderberg G (1977) Interferon treatment of osteogenic sarcoma—A clinical trial. Fogarty Intern. Center Proc., US Government Printing Office, Washington DC 28:377–381
Wang Y-M, Sutow WW, Rumsdahl MM, Perez C (1979) Age related pharmakokinetics of high dose methotrexate in patients with osteosarcoma. Cancer Treat Rep 63:405–410
Winkler K, Landbeck G (1977) Die Chemotherapie des Ewing-Sarkoms und des Osteosarkoms. Z Kinderchir. 21:1–20
Winkler K, Becker W, Kotz R (1978) Presentation of the collaborative osteosarcoma study COSS-77. Chimiother Oncol 1:25–228
Winkler K, Landbeck G (1981) Adriamycin zur Behandlung maligner osteogener Tumoren. Beitr Onkol 9:242–256
Winkler K, Beron G, Schellong G, Stollmann B, Prindull G, Lasson, U, Brandeis W, Henze G, Ritter J, Russe W, Stengel-Rutkowski L, Treuner J, Landbeck G (1982) Kooperative Osteosarkom Studie COSS-77: Ergebnisse nach über 4 Jahren. Klin Pediatr 194:251–256
Author information
Authors and Affiliations
Additional information
Supported by the Bundesministerium für Forschung und Technologie
The numbers refer to the code numbers of cooperating clinics (see Table 1)
Rights and permissions
About this article
Cite this article
Winkler, K., Beron, G., Kotz, R. et al. Adjuvant chemotherapy in osteosarcoma — Effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. J Cancer Res Clin Oncol 106 (Suppl 1), 1–7 (1983). https://doi.org/10.1007/BF00625042
Issue Date:
DOI: https://doi.org/10.1007/BF00625042